New Zealand has been chosen to be part of a late-stage trial for a new European Covid-19 vaccine.
The VLA2001 vaccine, created by company French biotech company Valneva, has already been trailed on approximately 4000 volunteers in Europe.
The company is now looking for 300 adults across New Zealand.
The participants must be older than 56 and not have previously had Covid-19 or received a Covid vaccine.
RNZ reporter Ella Stewart spoke with Director of Southern Clinical Trials Christchurch Dr Simon Carson who is the lead co-ordinating investigator for the New Zealand trial:
